Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9248662 | 0.83 | MAPKAPK2 (0.30) | — | |
| SCHEMBL425781 | 0.79 | ALDH1A1 (0.32) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL116183 | 0.79 | DRD2 (0.42) | PNMTMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL151908 | 0.79 | ADRA2A (0.36) | PNMTLMNA | |
| SCHEMBL9128476 | 0.79 | — | — | |
| SCHEMBL36333 | 0.78 | MAOA (0.39) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL10476775 | 0.78 | MAOA (0.39) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL9160477 | 0.78 | MAOA (0.39) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL2472916 | 0.77 | ADRA2A (0.35) | PNMTLMNA | |
| Hydrochloric Acid SCHEMBL585839 | 0.76 | MAOA (0.37) | KDM4EALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207017-A1 | APPARATUS AND METHODS FOR FILLING TEETH AND ROOT CANALS | SONENDO INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-3013277-B1 | APPARATUS AND METHODS FOR FILLING TEETH AND ROOT CANALS | SONENDO INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11701202-B2 | Apparatus and methods for filling teeth and root canals | SONENDO, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20180371291-A1 | COATING COMPOSITION, CURED FILM, LAMINATE, AND TIRE | BRIDGESTONE CORPORATION (JP) | 2018-12-27 | — | — | US | disclosed |
| US-20180360563-A1 | APPARATUS AND METHODS FOR FILLING TEETH AND ROOT CANALS | SONENDO, INC. | 2018-12-20 | — | — | US | disclosed |
| EP-3395916-A1 | COATING COMPOSITION, CURED FILM, LAMINATE, AND TIRE | Bridgestone Corporation (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180214247-A1 | SYSTEMS AND METHODS FOR OBTURATION OF ROOT CANALS | PERCEPTIVE CREDIT HOLDINGS III, LP | 2018-08-02 | — | — | US | disclosed |
| US-10035956-B2 | Compound and liquid-crystal composition employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-07-31 | — | — | US | disclosed |
| WO-2018075652-A1 | SYSTEMS AND METHODS FOR OBTURATION OF ROOT CANALS | SONENDO, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9877801-B2 | Apparatus and methods for filling teeth and root canals | SONENDO, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-5434264-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300642-A | α, α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0311010-B1 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | DU PONT MERCK PHARMA (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0532054-A1 | Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5173489-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0095587-B1 | DENTAL COMPOSITE AND PORCELAIN REPAIR | DEN-MAT CORPORATION (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0037604-B1 | INITIATOR SYSTEM FOR RADIATION CURABLE COMPOSITIONS, RADIATION CURABLE COMPOSITIONS CONTAINING SUCH AN INITIATOR SYSTEM, A PROCESS FOR CURING SAID COMPOSITIONS AND PRODUCTS COVERED THEREWITH | AKZO N.V. (NL) | 1984-08-22 | — | — | EP | disclosed |
| EP-0095587-A2 | Dental composite and porcelain repair | DEN-MAT CORPORATION (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4411822-A | A SULFONATE-CONTAINING BENZOIN DERIVATIVE, A GROUP 1A METAL SALT OF AN ORGANIC ACID AND A SOLVENT | AKZO N.V. (NL) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035956-B2 | Compound and liquid-crystal composition employing the same | ZYX, ZRANB2, CXXC4 | CD44 4269/4885PNMT 2951/4885KDM4E 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.